Lymphoma-derived extracellular vesicles inhibit CAR T cell function

2025/05/22 by Khadiza Siddika, Katie R Flaherty, Reuben Benjamin +2
Medicine · Biochemistry, Genetics and Molecular Biology · Engineering · #CAR-T cell therapy research #Extracellular vesicles in disease #Nanowire Synthesis and Applications

paper · doi:10.17912/micropub.biology.001646

Abstract

. We demonstrate that lymphoma-EV express B cell markers such as CD19 and CD20, which can be transferred to the CAR T cell membrane. In co-culture experiments, lymphoma-EV suppress the tumour-killing capacity of CAR T cells.

Related

• CD19.CAR T-cell–derived extracellular vesicles express CAR and kill leukemic cells, contributing to antineoplastic therapy
• CAR T cells: Building on the CD19 paradigm
• Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
• Biological and technical complexities in analyzing extracellular vesicle immune interactions in B‐cell malignancies
• Allogeneic CD19 CAR T cells armed with an anti-rejection CD70 CAR overcome antigen escape and evade alloimmune responses